Cargando…
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992737/ https://www.ncbi.nlm.nih.gov/pubmed/29899594 http://dx.doi.org/10.5301/GTND.2017.17029 |
| _version_ | 1783330090409525248 |
|---|---|
| author | Magistroni, Riccardo |
| author_facet | Magistroni, Riccardo |
| author_sort | Magistroni, Riccardo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5992737 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59927372018-06-11 Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease Magistroni, Riccardo G Tec Nefrol Dial Editoriale SAGE Publications 2018-03-13 2017-04 /pmc/articles/PMC5992737/ /pubmed/29899594 http://dx.doi.org/10.5301/GTND.2017.17029 Text en © 2017 SAGE Publications http://www.creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Editoriale Magistroni, Riccardo Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title | Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title_full | Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title_fullStr | Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title_full_unstemmed | Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title_short | Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease |
| title_sort | tolvaptan: clinical evidence for slowing the progression of autosomal dominant polycystic kidney disease |
| topic | Editoriale |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992737/ https://www.ncbi.nlm.nih.gov/pubmed/29899594 http://dx.doi.org/10.5301/GTND.2017.17029 |
| work_keys_str_mv | AT magistroniriccardo tolvaptanclinicalevidenceforslowingtheprogressionofautosomaldominantpolycystickidneydisease |